Motley Rice - Attorneys at Law
Navigation
Main navigation
Motley Rice represents clients across many areas.
Learn about the cases Motley Rice is actively representing clients in or cases that we've litigated previously.
Ozempic® users are filing lawsuits for vision loss, ileus, and other serious injuries.
Lawsuits allege talcum powder use is linked to reproductive organ cancer for women.
Lawsuits allege toxic heavy metals in baby food damage infants’ brain development.
Social media companies are being sued over alleged teenage mental health harms.
Meta is being sued for teenage mental health harms allegedly caused by Facebook and Instagram.
Women hurt by birth control drugs and devices may be eligible to sue over their injuries.
Studies link hair relaxers to uterine/ovarian cancer. Lawsuits seek to hold companies accountable.
Family members may have been eligible to file Camp Lejeune water contamination lawsuits.
People are filing gastroparesis lawsuits after using drugs like Ozempic®, Wegovy® and Mounjaro™.
While litigation can take years to complete from start to finish, our firm is always working for our clients, no matter how long it takes or how hard it gets.
Motley Rice attorneys and support personnel are dedicated to representing clients and working with co-counsel located throughout the United States and around the world.
Comprehensive, up-to-date news on the issues surrounding the litigation areas of Motley Rice LLC.
News, Learn about the latest happenings from lawsuits and other events impacting plaintiffs.
Motley Rice lawyers share their insights on litigation and more to inform people exploring their legal options.
This case is no longer active
Alexion Securities Class Action Lawsuit - Settlement
The Legal Team
Motley Rice LLC, as co-lead counsel, negotiated a $125 million settlement to resolve securities class action claims brought on behalf of certain investors in Alexion Pharmaceuticals, Inc.
The action, which was commenced in late 2016 in the U. S. District Court for the District of Connecticut, alleged Alexion and certain of its executives made materially false and misleading statements and omissions with respect to the source of Alexion’s reported revenues and Alexion’s sales and marketing practices for its flagship drug, Soliris® (eculizumab). The drug treats, among others, patients suffering from one of two ultra-rare diseases, paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The action further alleged the price of Alexion common stock was artificially inflated as a result of those allegedly false and misleading statements and omissions and declined when the truth was revealed through a series of partial disclosures.
The settlement resolves claims brought on behalf of all persons or entities who purchased or otherwise acquired the publicly traded common stock of Alexion from January 30, 2014 to May 26, 2017, inclusive, and were allegedly damaged thereby (subject to certain exclusions). The Class is represented by Motley Rice LLC and its co-counsel, Labaton Sucharow LLP. The Class Representatives are Erste Asset Management GmbH and Public Employee Retirement System of Idaho.
More details on the settlement terms can be viewed here on the settlement website.
A settlement hearing was held on December 20, 2023 before the Honorable Alvin W. Thompson at the Abraham Ribicoff Federal Building. The Court approved the settlement and the Plan of Allocation and awarded attorneys’ fees and expenses.
If you have questions about the settlement, please contact Motley Rice by telephone at (855) 481-8480 or via email at alexionsettlementquestions@motleyrice.com.